Effect of weight loss on nonalcoholic fatty liver disease

Journal of Clinical Gastroenterology

Volumn 43, Issue 10, 2009, Pages 970-974

  Patel, Anish A ^a   Torres, Dawn M ^a   Harrison, Stephen A ^a  

^a BROOKE ARMY MEDICAL CENTER   (United States)

Author keywords

Diet; Exercise; NAFLD; Weight loss

Indexed keywords

CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID RECEPTOR ANTAGONIST; RIMONABANT; TETRAHYDROLIPSTATIN; ANTIOBESITY AGENT;

BARIATRIC SURGERY; BODY WEIGHT; CALORIC RESTRICTION; DIET; GASTRIC BANDING; HUMAN; INSULIN RESISTANCE; LIPOGENESIS; LIVER BIOPSY; LIVER FIBROSIS; NONALCOHOLIC FATTY LIVER; OBESITY; PATIENT COUNSELING; PHYSICAL ACTIVITY; PRIORITY JOURNAL; REVIEW; STOMACH BYPASS; TREATMENT INDICATION; TREATMENT OUTCOME; WEIGHT REDUCTION; ANIMAL; EXERCISE; FATTY LIVER; METHODOLOGY;

ANIMALS; ANTI-OBESITY AGENTS; BARIATRIC SURGERY; EXERCISE; FATTY LIVER; HUMANS; INSULIN RESISTANCE; OBESITY; WEIGHT LOSS;

EID: 74949125012     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e3181b57475     Document Type: Review

References (46)

1. Kopelman PG. Obesity as a medical problem. Nature. 2000; 404:635-643.
2. Ogden CL, Carroll MD, Flegal KM. High body mass index for age among US children and adolescents, 2003-2006. JAMA. 2008;299:2401-2405.
3. Chitturi S, Farrell GC, Hashimoto E, et al. Non-alcoholic fatty liver disease in the Asia-Pacific region: definitions and overview of proposed guidelines. J Gastroenterol Hepatol. 2007;22:778-787. (Pubitemid 46915352)
4. Blackburn GL, Mun EC. Effects of weight loss surgeries on liver disease. Semin Liver Dis. 2004;24:371-379.
5. Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R, et al. Long term nutritional intake and the risk for nonalcoholic fatty liver disease (NAFLD): a population based study. J Hepatol. 2007;47:711-717.
6. Assy N, Kamayse I, Nseir W, et al. Soft drink consumption linked with fatty liver in the absence of traditional risk factors. Can J Gastroenterol. 2008;10:811-816.
7. Musso G, Gambino R, DeMichieli F, et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology. 2003;37: 367-372.
8. Cortez-Pinto H, Jesus L, Barros H, et al. How different is the dietary pattern in nonalcoholic steatohepatitis patients? Clin Nutr. 2006;25:816-823.
9. Capanni M, Calella F, Biagini MR, et al. Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with nonalcoholic fatty liver disease: a pilot study. Aliment Pharmacol Ther. 2006;23:1143-1151.
10. Bruno RS, Dugan CE, Smyth JA, et al. Green tea extract protects leptin-deficient, spontaneously obese mice from hepatic steatosis and injury. J Nutr. 2008;138:323-331.
11. Harrison SA, Day CP. Benefits of lifestyle modifications in NAFLD. Gut. 2007;56:1760-1769.
12. Clark JM. Weight loss as a treatment for nonalcoholic fatty liver disease. J Clin Gastroenterol. 2006;40(suppl 1):S39-S43.
13. Drenick EJ, Simmons F, Murphy JF. Effect on hepatic morphology of treatment of obesity by fasting, reducing diets and small-bowel bypass. N Engl J Med. 1970;282: 829-834.
14. Huang MA, Greenson JK, Chao C, et al. One-year intense nutritional counseling results in histological improvement in patients with nonalcoholic steatohepatitis: a pilot study. Am J Gastroenterol. 2005;100:1072-1081.
15. Lewis MC, Phillips ML, Slavotinek JP, et al. Change in liver size and fat content after treatment with Optifast very low calorie diet. Obes Surg. 2006;16:697-701.
16. Thomas EL, Brynes AE, Hamilton G, et al. Effect of nutritional counseling on hepatic, muscle and adipose tissue fat content and distribution in nonalcoholic fatty liver disease. World J Gastroenterol. 2006;12:5813-5819.
17. Larson-Meyer DE, Newcomer BR, Heilbronn LK, et al. Effect of 6-month calorie restriction and exercise on serum and liver lipids and markers of liver function. Obesity (Silver Spring). 2008;16:1355-1362.
18. Chun-Lin W, Li L, Jun-Fen F, et al. Effect of lifestyle intervention on non-alcoholic fatty liver disease in Chinese obese children. World J Gastroenterol. 2008;14:1598-1602.
19. Andersen T, Gluud C, Franzmann MB, et al. Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol. 1991;12:224-229.
20. Westerbacka J, Lammi K, Hakkinen A-M, et al. Dietary fat content modifies liver fat in overweight nondiabetic subjects. J Clin Endocrinol Metab. 2005;90:2804-2809.
21. Petersen KF, Dufour S, Befroy D, et al. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes. 2005;54:603-608.
22. Yamamoto M, Iwasa M, Iwata K, et al. Restriction of dietary calories, fat and iron improves non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2007;22:498-503.
23. Allard JP, Aghdassi E, Mohammed S, et al. Nutritional intake and hepatic hepatic fatty acid composition in NAFLD: a crosssectional study. J Hepatol. 2008;2:300-307.
24. Spadaro L, Magliocco O, Spampinato D, et al. Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. Dig Liver Dis. 2008;40:194-199.
25. Yancy WS Jr, Olsen MK, Guyton JR, et al. A lowcarbohydrate, ketogenic diet versus a low-fat diet to treat obesity and hyperlipidemia: a randomized, controlled trial. Ann Intern Med. 2004;140:769-777.
26. Westman EC, Yancy WS Jr, Olsen MK, et al. Effect of a lowcarbohydrate, ketogenic diet program compared to a low-fat diet on fasting lipoprotein subclasses. Int J Cardiol. 2006;110:212-216.
27. Tendler D, Lin S, Yancy WS Jr, et al. The effect of a lowcarbohydrate, ketogenic diet on nonalcoholic fatty liver disease pilot study. Dig Dis Sci. 2007;52:589-593.
28. Kruk J. Physical activity in the prevention of the most frequent chronic diseases: an analysis of the recent evidence. Asian Pac J Cancer Prev. 2007;8:325-338.
29. He Y, Zhang H, Fu F. The effects of swimming exercise on high-fat-diet-induced steatohepatitis. J Sports Med Phys Fitness. 2008;48:259-265.
30. Haram PM, Kemi OJ, Lee SJ, et al. Aerobic interval training vs. continuous moderate exercise in the metabolic syndrome of rats artificially selected for low aerobic capacity. Cardiovasc Res. 2009;81:723-732.
31. Suzuki A, Lindor K, St Saver J, et al. Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease. J Hepatol. 2005;43:1060-1066.
32. Baba CS, Alexander G, Kalyani B, et al. Effect of exercise and dietary modification on serum aminotransferase levels in patients with nonalcoholic steatohepatitis. J Gastroenterol Hepatol. 2006;21:191-198.
33. Hickman IJ, Jonsson JR, Prins JB, et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut. 2004;53: 413-419.
34. Ueno T, Sugawara H, Sujaku K, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol. 1997;27:103-107.
35. Kantartzis K, Thamer C, Peter A, et al. High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease. Gut. 2008. [Epub ahead of print].
36. Harrison SA, Fincke C, Helinski D, et al. A pilot study of orlistat treatment in obese, nonalcoholic steatohepatitis patients. Aliment Pharmacol Ther. 2004;20:623-628.
37. Assy N, Hussein O, Abassi Z. Weight loss induced by orlistat reverses fatty infiltration and improves hepatic fibrosis in obese patients with non-alcoholic steatohepatitis. Gut. 2007;56:443-444. (Pubitemid 46579783)
38. Zelber-Sagi S, Kessler A, Brazowsky E, et al. A double-blind randomized placebo-controlled trial of orlistat for treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2006;4:639-644.
39. Harrison SA, Brunt EM, Fecht WJ, et al. Orlistat in the treatment of overweight patients with nonalcoholic steatohepatitis (NASH): a multi-centered, randomized, prospective trial. Gastroenterology. 2007;4(suppl 2):T1059.
40. Banasch M, Goetze O, Schmidt WE, et al. Rimonabant as a novel therapeutic option for nonalcoholic steatohepatitis. Liver Int. 2007;27:1152-1155.
41. Woods SC. Role of the endocannabinoid system in regulating cardiovascular and metabolic risk factors. Am J Med. 2007; 120:S19-S25.
42. Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med. 2005;353:2121-2134.
43. Scheen AJ, Finer N, Hollander P, et al. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomized controlled study. Lancet. 2006;368:1660-1672.
44. Dixon JB, Bhathal PS, Hughes NR, et al. Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology. 2004;39:1647-1654.
45. Barker KB, Palekar NA, Bowers SP, et al. Non-alcoholic steatohepatitis: effect of roux-en-Y gastric bypass surgery. Am J Gastroenterol. 2006;101:368-373.
46. Liu X, Lazenby AJ, Clements RH, et al. Resolution of nonalcoholic steatohepatitis after gastric bypass surgery. Obes Surg. 2007;17:486-492.